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Aims: To corroborate protective effects of a range of drug treatment modalities against overdose 23 
mortality risk. 24 
Design & Methods: Nested case-control study, with incidence density sampling, selecting controls 25 
retrospectively at each case event. Cases and controls came from a sub-cohort of opioid dependent 26 
patients (N=4,444) from two Italian regions (Lazio and Piedmont). From 1998 to 2005, there were 91 27 
overdose deaths (cases) matched to 352 controls. The primary outcome was overdose mortality and 28 
the primary exposure was drug treatment: opioid agonist treatment (OAT), opioid detoxification, 29 
residential community, psychosocial, and other pharmacological treatment. Conditional logistic 30 
regression models generated intervention effects comparing mortality risk in and out of treatment, 31 
adjusting for confounding variables.  32 
Results: Overall, drug treatment reduced overdose mortality risk by 80% (adjusted odds ratio [AOR]: 33 
0.18, 95%CI: 0.10-0.33, p<0.001) compared to being out of treatment. There was a particularly strong 34 
protective effect of OAT on overdose mortality (AOR: 0.08, 95%CI: 0.03-0.23, p<0.001) compared to 35 
being out of treatment. There was evidence of a substantially elevated risk of overdose in the first 36 
month of leaving treatment (AOR=23.50, 95%CI: 7.84-70.19, p<0.001) compared to being in 37 
treatment.  38 
Discussion & Conclusions: The nested case-control design strengthened earlier findings that OAT in 39 
Italy has strong protective effects on overdose mortality risk, much stronger than has been previously 40 
seen in other Western European settings. 41 
Key words: Opioid agonist treatment, heroin dependence, drug treatment, methadone maintenance, 42 





In Western Europe, there is a substantially elevated risk of mortality for people who use illicit opioids 46 
compared to the general population (1). Currently, overdose is the leading cause of death among this 47 
population and is increasingly prevalent (2-4). Opioid agonist treatment (OAT) is an essential 48 
medicine for treating opioid dependence (5) and multiple studies have shown that the risk of overdose 49 
is substantially higher for people who are not engaged in OAT (6-10). This risk has been found to be 50 
more pronounced in the month immediately following treatment (i.e. completing or leaving treatment) 51 
(6, 7, 11, 12).  52 
Previously, we investigated the protective effect of multiple treatment modalities on overdose 53 
mortality risk and found that “retention in any treatment” was strongly protective, reducing overdose 54 
risk by 90% (hazard ratio [HR]=0.09, 95% confidence intervals [CI]=0.04-0.19) (13). The previous 55 
study was a large prospective cohort (N=10,258) with a comparatively short exposure period out of 56 
treatment (n=2914 person-years) and relatively few overdose deaths (n=41). Where data on exposures 57 
are not updated, and need to be collected, the nested case-control design is beneficial as it is a more 58 
efficient way of increasing power and can provide direct estimates of interventions effects (14).  59 
In this study, we undertook a nested case-control design using incidence density sampling that would 60 
extend the follow-up period, decrease the sample size, and more efficiently strengthen and test the 61 





Details of the original cohort are described elsewhere (7). Briefly, participants were recruited at 115 65 
of 554 (23.0%) public treatment centres working within the National Health Service in Italy during 66 
1998-99 (15). The original VEdeTTE cohort consisted of 10,454 people who use heroin. From this 67 
broader cohort, we had capacity to conduct a further study in two Italian regions (Piedmont and 68 
Lazio), which comprised 4,444 participants. Among this sub-cohort, from September 1998 to 31 69 
December 2005, 316 deaths occurred and 95 were due to overdose (Figure S1).  70 
Design 71 
This study is a nested case-control design where the cases were those who had fatally overdosed over 72 
the follow-up period. Adopting an incidence density sampling procedure, four controls for each 73 
overdose death were randomly extracted from the cohort (coded as alive on the date of the case’s 74 
death, i.e. the index date for controls). Participants were matched on region, age (i.e. the age of the 75 
case ±5 years), and sex. Participants could be matched with multiple cases and a case could 76 
potentially be a control of a case who had died before them. In total, 380 controls were extracted.  77 
Of 95 cases, 4 were subsequently excluded due to missing treatment participation information (see 78 
participant flowchart in Figure S2). Out of 380 controls, 28 were excluded (16 controls paired with 79 
the excluded cases and 12 controls had missing treatment information). A total of 91 cases and 352 80 
controls were included in the study.  81 
Measures 82 
The primary outcome was death due to overdose. Assessors who extracted data from clinical records 83 
were blind to whether subjects were a case or control. Vital status information was first retrieved from 84 
the clinical records retained from the participant’s treatment centre, then (if unavailable) from the 85 
Registry Office of the last municipality of residence, which keeps track of any change in residence or 86 
vital status. Follow-up was completed for 97.8% of subjects. Cause of death was coded according to 87 
the International Classification of Diseases (ICD) (9th revision), and overdose deaths were consistent 88 
with the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) definition at the 89 
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time of extraction and the previous study (13, 16). The codes corresponded mainly to the causes of 90 
death, ‘drug dependence’, and ‘poisoning’ (including accidental). 91 
The primary exposure was drug treatment type. Information on any treatment administered in the last 92 
two months before the death for cases, and index date for controls, were collected from clinical 93 
records, including type of treatment, starting and closing date, dose, frequency, and treatment status 94 
(incomplete or completed). There were 13 treatment types that were aggregated into five groups for 95 
analysis: OAT (methadone maintenance and buprenorphine maintenance treatments), opioid 96 
detoxification (methadone detoxification and buprenorphine detoxification), other pharmacological 97 
treatment (naltrexone maintenance, detoxification with non-opioid drugs, and therapy with other 98 
psychotropic drugs), residential community (residential and semi-residential treatment facilities), and 99 
psychosocial (social advice and counselling). For those out of treatment in the last two months before 100 
the index date, information on treatments (type and date of last administration) in the month before 101 
discharge/last attendance was collected. Being considered “out of treatment” differed between 102 
modalities:  103 
i) Pharmacological treatment: from the second day of absence;  104 
ii) residential community: from the second day after leaving treatment; and 105 
iii) psychosocial treatment: from the day after the first missed visit. 106 
Baseline demographic data assessed at enrolment in the VEDeTTE cohort included sex, age, 107 
educational level, marital status, employment, and housing status. Drug use and risk behaviours 108 
included type and frequency of drug use, heroin administration method, age at first heroin use, history 109 
of overdose, health risk behaviours, mental and physical health status, voluntary access to drug 110 
treatment and criminality in the last 12 months (15). 111 
Statistical analysis 112 
The study aimed to assess mortality risk during and immediately after periods of drug treatment and 113 
test and replicate the findings from the previous paper (7).  The nested case-control study had 99% 114 
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power to detect a difference in mortality risk of at least 3 times between in and out of treatment, 115 
assuming 30% exposure to drug treatment. 116 
The effect of being in or out of treatment at the time of death for overdose was assessed using a 117 
conditional logistic regression model (as the case-controls were matched). The nested design and 118 
sampling of controls meant that the estimated odds ratios approximate risk ratios and can be directly 119 
compared to the results from the previous cohort (14). The same model was applied to evaluate the 120 
effect of time since the disruption in treatment. 121 
Potential confounders were identified using univariable logistic regression models. Variables 122 
associated with the outcome (p-value ≤0.2) were included in the multivariable models (homelessness, 123 
HIV positivity, alcohol use, legal problems and overdose reported at baseline). Missing information at 124 
baseline was negligible for any of the assessed characteristics.  125 
Ethics 126 
At enrolment into treatment, participants gave informed consent to participate in this study. Study 127 






We followed up 91 cases and 352 controls for an average of 6.8 years (from 1998 to 2005). Table 1 132 
shows demographic information for cases, controls and the original VEdeTTE sub-cohort. Of those in 133 
treatment at the index date, 20 (8.8%) were cases and 207 (91.2%) were controls. Most participants 134 
were in OAT (52.9%), psychosocial treatment (18.9%), residential community (15.4%), or opioid 135 
detoxification (11.9%). For those out of treatment, the most commonly recorded last treatment was 136 
psychosocial (30.1%), followed by OAT (26.8%) and opioid detoxification (24.1%).  137 
< Table 1 > 138 
Table 2 shows that, compared to those out of treatment, those in treatment showed a reduced risk of 139 
overdose mortality (OR=0.19, 95% CI: 0.10-0.33, p<0.001). This effect remained stable after 140 
controlling for potentially confounding variables (AOR=0.18, 95%CI: 0.10-0.33). The effect sizes 141 
differed by treatment type with only OAT (AOR=0.08, 95%CI: 0.03-0.23, p<0.001) and residential 142 
community (AOR=0.22, 95%CI: 0.06-0.76, p=0.019) yielding strong protective effects. The 143 
unadjusted risk of death for overdose was 5.40 (95%CI: 3.05-9.56, p<0.001) for those out of 144 
treatment, and the adjusted risk of death was 5.46 (95%CI: 3.02-9.88, p<0.001). In the first 30 days 145 
after leaving treatment, the risk of overdose was substantially higher (OR=15.07, 95%CI: 5.79-39.22, 146 
p<0.001), and slightly strengthened after adjusting for potentially confounding variables 147 
(AOR=23.50, 95%CI: 7.84-70.19, p<0.001).  148 





We corroborated earlier findings of the protective effect of drug treatment in Italy. Using a nested 152 
case-control design, we found that overdose mortality was more than 23 times higher in the first 153 
month out of treatment compared to in treatment for people who are heroin dependent. OAT had a 154 
very strong protective effect with a reduction in the risk of overdose mortality by over 90%.  155 
This study strengthens and elaborates on previous findings that drug treatment, especially OAT, is 156 
particularly protective in Italy. The crude mortality rate estimated previously for the VEdeTTE cohort 157 
was 12.0 per 1000 person years (17), lower than what was estimated for Western European cohorts 158 
previously (22.2 [95%CI: 19.6-24.7] per 1000 person years) (3). Therefore, it may be that OAT in 159 
Italy is more effective in reducing overdose risk compared to other European settings. 160 
There are several limitations that need to be considered. First, our treatment exposure refers only to 161 
whether the case or control was engaged in treatment for two months, so we could not test whether 162 
treatment duration contributed to mortality risk. It has been estimated that increasing the average 163 
treatment duration by 3 months could incur a 5% decrease in mortality (18). Also, our treatment 164 
exposure refers to centres participating in the study and may misclassify other treatment types as 165 
being ‘out of treatment’ (e.g. private clinics).  Nonetheless, the number of people who use heroin 166 
attending private clinics is estimated to be low in Italy (19), the treatment effect was considerable, and 167 
misclassification would be more likely to lead to an under-estimate.  168 
Compared to other settings, the quality of clinical records kept for OAT and therapeutic communities 169 
in Italy is of good quality. For therapeutic communities, there is a refund system that is based on 170 
treatment administration and days of attendance. Maintaining clinical records is not compulsory for 171 
the other types of treatment; therefore, the completeness of those clinical records could be variable. 172 
Due to the study design, however, any recording bias is likely to be non-differential as it can affect 173 
both cases and controls.  174 
We strengthened the assertion that drug treatment in Italy is protective of overdose mortality; it is 175 
necessary to educate people who use opioids about the risk of overdose, especially in the period that 176 
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Table 1. Descriptive characteristics and comparisons of the cases and controls, the VEdeTTE 
sub-cohort and treatment engagement 








 N = 91 N = 352 p-values N = 4444 
Men 73 (80.2) 282 (80.1) 0.982 3671 (82.6) 

























































Homeless 8 (8.8) 7 (2.0) 0.005 98 (2.2) 
Unemployed 41 (45.1) 129 (36.6) 0.276 1479 (33.3) 
Voluntary drug treatment access 78 (85.7) 285 (81.0) 0.488 3701 (83.3) 
Cocaine use 35 (38.5) 149 (42.3) 0.309 1718 (38.7) 
Alcohol use 26 (21.3) 84 (17.9) 0.438 758 (17.1) 
History of overdose 81 (66.4) 200 (42.6) <0.001 1919 (43.2) 
HIV+ 29 (8.2) 9 (9.9) 0.616 429 (9.7) 
Psychiatric comorbidities 10 (11.0) 21 (6.0) 0.094 294 (6.6) 
Age at first heroin use mean 
(SD) 
19.3 (4.2) 19.7 (4.4) 0.406 19.7 (4.5) 
Legal problems in the last 12 
months 





















 N = 227 N = 216   
Cases 20 (8.8) 70 (32.4)   





















Residential community 35 (15.4) 29 (13.4)   
Psychosociald 43 (18.9) 65 (30.1)   
Other pharmacologicale <5 (0.9) 12 (5.6)   
a Three of the 347 participants said they did not go to school 
b Among those in treatment at the index date 
c The last treatment for those out of treatment at the index date 
d Psychosocial alone: psychosocial combined with other treatments is included in the other lines.  




Table 2. Odds ratio (OR) and 95% confidence intervals (95% CI) of overdose mortality for 
people with heroin dependence in and out of treatment (n = 443).  




95% CI p-value Adjusted 
ORa 
95% CI p-value 
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  Detoxification 
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  0.038 
  0.008 













  0.142 
  0.017 
  0.126 
In treatment 















Time since last treatment 
  ≤30 days 






















Note: there were no overdose deaths reported for buprenorphine detoxification or other pharmacological treatment.  
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